Products & ReviewLife Sciences

AbZelect™ and AbZelectPRO™ cell line development platforms

AbzenaAvailable: Worldwide

AbZelect™ and AbZelectPRO™ support cell line development (CLD) to rapidly progress therapeutic protein and recombinant vaccine projects while de-risking the journey to Investigational New Drug (IND) application.

Request Pricing

Receive your quote directly from the manufacturer.

Ease of Use
After Sales Service
Value for Money
Write your own review

Designed for traditional protein programs, such as antibodies, Abzena’s proprietary, license-free AbZelect™, is optimized across the three key areas of vector, host cell line, and process. It provides improved cell doubling times, viable cell densities, and robust and stable cell lines.

The AbZelectPRO™ platform combines AbZelect™ with 2G UNic® premium vector technology to boost expression levels and generate higher-producing, stable cell lines expressing proteins including bispecifics, fusions, and other novel modalities.

By streamlining the CLD process, the AbZelect™ platforms can progress your project from sequencing to research cell banks in 15 weeks, helping to deliver your project to the clinic faster.

Our AbZelect™ platforms promote the in-depth characterization of multiple candidates at early stages through the generation of multiple fast stable pools, enabling rapid identification and mitigation of risk.

Product Overview